plification and sequencing are shown in the figure. A first strand cDNA synthesis kit (Pharmacia) with poly-T primer and specific COX8 primer (F 1–22) was used for cDNA amplification between nucleotides 22 and 472 (figure A), according to the nucleotide numbers reported by Rizzuto *et al.*⁷ The 5' end of COX8 cDNA, before nucleotide 22, was amplified with the 5'-RACE kit (Life Technology/Gibco-BRL) and specific COX8 primer (R 231–250, figure B). Overlapping PCR fragments were sequenced using the dideoxynucleotide chain termination method with fluorescent dideoxynucleotides on an Applied Biosystem 373A DNA sequencer (Perkin Elmer/ABI). We found a hitherto unidentified sequence of 42 nucleotides at the 5' end of the cDNA, and the rest of the COX8 cDNA sequence was identical to that previously described by Rizzuto *et al.*⁷ (figure). From nucleotides –42 to +472, there were no mutations in either the affected or healthy people in the COX8 cDNA.

The promoter region of the COX8 gene, the part of the gene that has not yet been identified, was not analysed. However, all the mutations so far identified in FHC have been described, either in the coding regions of the gene (mutations in MYH7 encoding the β myosin heavy chain³), or in an intronic splicing site (mutation in the splice donor sequence of intron 15 of the cardiac troponin T gene⁵). By analogy with all the data available for FHC, we therefore conclude that the COX8 gene is very unlikely to be the disease gene of the CMH4 locus responsible for FHC.

We are indebted to the family members for their invaluable participation. We are also grateful to J Weissenbach, P Millasseau, C Cruaud, and C Caloustian for their help in sequencing at the Généthon (Evry, France) and to L Feller, O Dubourg, A Hagege, J B Bouhour, and R Isnard for their contribution to clinical diagnoses. This work was supported by INSERM (Réseau de recherche clinique No 492010) and the Association Française contre les Myopathies. GB is recipient of a grant from the Fondation Bettencourt-Schuller.

GISÈLE BONNE
LUCIE CARRIER
KETTY SCHWARTZ
Unité de Recherche 153 de l'INSERM,
Pavillon Rambuteau,
Groupe Hospitalier Pitié-Salpêtrière,
47 Boulevard de l'Hôpital,
75651 Paris CEDEX 13, France.
MICHEL KOMAJDA
Service de Cardiologie,
Groupe Hospitalier Pitié-Salpêtrière,
Paris, France.

- 1 Maron BJ, Ferrans VJ. Ultrastructural features of hypertrophied human ventricular myocardium. In: *Progress in cardiovascular diseases*. 1978;207–38.
- 2 Maron BJ, Nichols PF, Pickle LW, *et al.* Patterns of inheritance in hypertrophic cardiomyopathy. Assessment by M-mode and two-dimensional echocardiography. *Am J Cardiol* 1984;53: 1087–94.
- 3 Schwartz K, Carrier L, Guicheney P, Komajda M. The molecular basis of familial cardiomyopathy. *Circulation* 1995;91:1–9.
- 4 Geisterfer-Lowrance AAT, Kass S, Tanigawa G, *et al.* A molecular basis for familial hypertrophic cardiomyopathy: a β cardiac myosin heavy chain gene missense-mutation. *Cell* 1990;62:999–1006.
- 5 Thierfelder L, Watkins H, MacRae C, *et al.* α -tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. *Cell* 1994;77:701–12.
- 6 Carrier L, Hengstenberg C, Beckmann JS, *et al.* Mapping of a novel gene for familial hypertrophic cardiomyopathy to chromosome 11. *Nature Genet* 1993;4:311–13.
- 7 Rizzuto R, Nakase H, Darras B, *et al.* A gene specifying subunit VIII of human cytochrome c oxidase is localized to chromosome 11 and

is expressed in both muscle and non-muscle tissues. *J Biol Chem* 1989;264:10595–600.

- 8 Hatefi Y. The mitochondrial electron transport and oxidative phosphorylation system. *Annu Rev Biochem* 1985;54:1015–69.
- 9 Gournay-Toulemonde V, Munnich A, Bouhour JB, *et al.* Hypertrophic cardiomyopathy caused by cytochrome c oxidase deficiency. *Presse Med* 1994;23:1475–9.
- 10 Ozawa T. Mitochondrial cardiomyopathy. *Herz* 1994;19:105–18.
- 11 Schwartz K, Dufour C, Fougerousse F, *et al.* Exclusion of myosin heavy chain and cardiac actin gene involvement in hypertrophic cardiomyopathies of several French families. *Circ Res* 1992;71:3–8.
- 12 Bonne G, Seibel P, Possekkel S, Marsac C, Kadenbach B. Expression of human cytochrome c oxidase subunits during fetal development. *Eur J Biochem* 1993;217:1099–107.

BOOK REVIEWS

If you wish to order or require further information regarding the titles reviewed here, please write to or telephone the BMJ Bookshop, PO Box 295, London WC1H 9JR. Tel 0171 383 6244. Fax 0171 383 6662. Books are supplied post free in the UK and for BFPO addresses. Overseas customers should add 15% for postage and packing. Payment can be made by cheque in sterling drawn on a UK bank or by credit card (Mastercard, Visa, or American Express) stating card number, expiry date, and full name. (The price and availability are occasionally subject to revision by the Publishers.)

Assessing Genetic Risks: Implications for Health and Social Policy. Editors L B Andrews, J E Fullerton, N A Holtzman, A G Motulsky. Committee on Assessing Genetic Risks, Division of Health Sciences Policy, Institute of Medicine. (Pp 338; £36.95) Washington, DC: National Academy Press. 1994. ISBN 0-309-04798-6.

This fascinating report provides a comprehensive account of the "promises and problems in genetic testing". The deliberations of the 20 committee members were informed by a series of papers and discussions at workshops, meetings, and a public forum.

The first 28 pages comprises the Executive Summary and provides the reader with a useful synopsis of the 70 plus recommendations. Many of their recommendations mirror those found in the Nuffield report on ethical issues in genetic screening (London: Nuffield Foundation, 1993). One example is the creation of a National Advisory Committee Working Group on Genetic testing to oversee professional practice and determine when new genetic tests are ready for wide scale use in medical practices. The Nuffield report proposes the setting up of a central coordinating body to review genetic screening programmes and monitor their implementation and outcome.

The report covers the following issues: Genetic testing and assessment; Laboratory issues in human genetics; Issues in genetic counselling; Public education in genetics; Personnel issues in human genetics; Financing of genetic testing and screening; Social, legal, and ethical implications of genetic testing; and Research and policy agenda.

The numerous references for each of these topics are situated at the end of each chapter. The report continuously emphasises the need to respect the autonomy of people in the way they use genetic information.

I was delighted to see two pages devoted to "Recognizing Social and Cultural Differences". The report identified the need for a variety of information and education on genetics, with balanced descriptions, in a culturally acceptable manner and at an appropriate time. I found the term "teachable moment" a very useful concept (that is, when the person is most able to comprehend the full significance of the information). Recommendations about developing innovative information materials such as interactive computer systems were noted on several occasions. As in the Nuffield report, reference is made to the training needs of primary care practitioners.

It is of interest that the Chairman of the Committee (A G Motulsky) felt the need to add a separate note to the Preface. In it he pointed out that while the majority of the committee favoured voluntary participation in neonatal screening, a minority felt that mandatory screening for phenylketonuria (PKU) and hypothyroidism would be a simpler solution.

On a more personal note, he stated that information about sickle cell trait that is incidentally detected in neonatal screening is difficult to withhold and should be given to the mother with appropriate genetic counselling. This seems to be in contrast to the more confusing recommendation of the report: "When carrier status may be incidentally determined in newborn screening (eg, in sickle cell screening), parents should be informed in advance about the benefits and limitations of genetic information, and that this information is not relevant to the health of their child. If they ask for the results of the incidentally determined carrier status for their own reproductive planning, it should be communicated to them in the context of genetic counselling, and they should be informed that misattributed paternity could be revealed."

This has been a most enjoyable book to read and I would strongly recommend it to anybody interested in the broader issues raised by genetic screening and testing.

ELIZABETH N ANIONWU

Genetics in Neurology. Bailliere's Clinical Neurology. Editor A E Harding. (Pp 452; £27.50) UK: Harcourt Brace. 1994.

How much of this rapidly expanding field can you cover in 452 pages (including references and index)? To their credit, the editor and authors of this text have included all the inherited neurological diseases which are likely to be of major interest to clinical neurologists and clinical geneticists. In addition, judging by the number of times this reviewer's copy was borrowed, molecular geneticists working with these diseases will also find the chapters enlightening.

The chapters are all well written, comprehensible, and, in addition to providing excellent reviews of their subjects, provide an insight into the issues of genetic and phenotypic heterogeneity as they relate to the specific disease groups. The chapters on hereditary ataxias (Banfi and Zoghbi) and

human prion diseases (Collinge and Palmer) in particular show how we are only just beginning to understand the relationships between genotype and phenotype.

From the point of clinical applicability, the discussion, in the chapter on the muscular dystrophies (Bushby), on the use of dystrophin DNA and protein analyses in suspected Xp21 dystrophy patients, carriers, and at risk pregnancies, is likely to be of particular interest.

In addition to the expected topics of Alzheimer's disease, prion diseases, movement disorders, ataxias, neuropathies, neuro-nopathies (spinal muscular atrophies), mitochondrial diseases, muscular dystrophies, and myotonias three chapters cover disorders where the genetic component is less well understood, the epilepsies, multiple sclerosis, and neurological tumours. The last of these does include brief discussions on the genetic neurocutaneous syndromes but it deals largely with the molecular genetics of sporadic neurological tumours. These are too often omitted from texts discussing neurological genetics, and this chapter provides a valuable detailed discussion on the roles of chromosome loss and gene mutations (p 53) in specific CNS tumours.

All of the 12 chapters are as current as the publication date of August 1994 allowed. Indeed the only major additions/updates a clinical neurologist is likely to need are Machado-Joseph disease, which was recently appended to the list of trinucleotide repeat expansions affecting the CNS, the gene for Emery-Dreifuss muscular dystrophy, and the gene(s?) for the autosomal recessive spinal muscular atrophies of childhood.

There appear to be very few typographical errors, the most notable being the substitution

of heterozygotes for homozygotes at one point in the description of the modifying effect of codon 129 status on age at onset for inherited prion diseases (p 248).

Overall this volume has much to commend it, including the price. It should certainly be read once by clinical geneticists (and neurologists) especially if they feel the need to "catch up" on the recent past advances in the molecular genetics of the major groups of inherited neurological diseases.

JOHN MACMILLAN

Textbook of Fetal Physiology. Editors G D Thorburn, R Harding. (Pp 468; £65.00.) Oxford: Oxford Medical Publications. 1994. ISBN 0198577486.

The preface to this excellent volume states that it aims to act as a companion to the classical texts on adult physiology for medical training at undergraduate and postgraduate levels. In fact it fills an important niche in the market owing to the paucity of readable books on human fetal development and physiology. Indeed there is also a rapidly increasing demand for this type of general textbook from human molecular geneticists. As the combined efforts of human genome project related research generate an ever expanding list of cloned genes associated with specific human diseases, the task remains of elucidating how any gene product actually causes the associated disease. Inevitably questions of gene expression during development arise. The textbook of fetal physiology will provide a valuable reference book for molecular and cell biologists asking these questions.

The book has chapters from a large number of contributors on topics ranging from placental function, through development of individual organ systems and physiological mechanisms, ending with chapters on maternal aspects of pregnancy. For each organ system a first chapter addresses the embryological, structural, and cellular aspects of development. One or more subsequent chapters then address an important physiological function of that organ system. Hence, the chapter on development of the respiratory system is followed by a chapter on fetal lung maturation, and that on renal function is accompanied by one on fetal fluid balance. There is a particularly extensive section on different aspects of development of the nervous system. The book is well illustrated and readable and will undoubtedly be a useful addition to many medical and basic science bookshelves.

ANN HARRIS

NOTICE

Gene Therapy

The 3rd International Karger Symposium on Gene Therapy will be held on 22-24 October 1995 in Basel, Switzerland. For further information contact: S Karger AG, Congress Secretariat, PO Box, CH-4009 Basel, Switzerland. Tel: +41/61/306 11 11, fax: +41/61/306 14 34.